Lenalidomide Sandoz 20 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, leading to the targeted degradation of the transcription factors Ikaros and Aiolos. This action modifies the immune environment, suppresses angiogenesis, and directly inhibits the proliferation of malignant plasma cells and other tumor cells.

The specific dose of lenalidomide is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and concomitant therapies. Dosing regimens can differ between multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, and should always follow the prescriber’s instructions.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended because the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory drug, offering greater potency and a more favorable safety profile than thalidomide, while being less myelosuppressive than pomalidomide. It retains the core mechanism of cereblon binding but provides improved efficacy in certain hematologic malignancies, making it a preferred option in many treatment protocols.

Store the capsules at ambient temperature, preferably below 25 °C, in their original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the capsules appear discolored.

Lenalidomide is taken orally, usually once daily, with or without food, and the capsule should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and avoid crushing or opening the capsule.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, secondary primary malignancies, and teratogenic effects that can cause fetal harm. Prompt medical attention is required if any of these events are suspected.

Lenalidomide should not be used by pregnant women or women who could become pregnant without reliable contraception, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with severe renal impairment who have not had appropriate dose adjustments. Clinicians must evaluate each patient’s suitability before initiating therapy.